Trial · NCT00908141
GM-CSF in Treating Patients With Relapsed Prostate Cancer
NCT00908141, Phase 2, Completed, Case Comprehensive Cancer Center; results first posted 2013-08-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GM-CSF in Treating Patients With Relapsed Prostate Cancer. Trials, record NCT00908141. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00908141
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GM-CSF in Treating Patients With Relapsed Prostate Cancer
- NCT number
- NCT00908141
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 17 participants, actual
- Lead sponsor
- Case Comprehensive Cancer Center
- Conditions
- Prostate Cancer
- Interventions
- sargramostim
- First posted
- 2009-05-25
- Last updated
- 2013-08-23
- Results first posted
- 2013-08-09
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Prostate Specific Antigen (PSA) Response | post treatment at 9 weeks | The number of patients with PSA modulation defined as PSA decline of at least 50% |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Prostate Specific Antigen (PSA) Response | post treatment at 9 weeks | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Prostate Specific Antigen (PSA) Response | Group A: Sargramostim (Days 1-14) | 2 | participants | ||
| Prostate Specific Antigen (PSA) Response | Group B: Sargramostim (3 x Week) | 0 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group A: Sargramostim (Days 1-14) | 8 | |
| Overall Study | STARTED | Group B:Sargramostim (3 x Week) | 9 | |
| Overall Study | COMPLETED | Group A: Sargramostim (Days 1-14) | 8 | |
| Overall Study | COMPLETED | Group B:Sargramostim (3 x Week) | 8 | |
| Overall Study | NOT COMPLETED | Group A: Sargramostim (Days 1-14) | 0 | |
| Overall Study | NOT COMPLETED | Group B:Sargramostim (3 x Week) | 1 |
Source ClinicalTrials.gov
Adverse events100
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain or cramping | Gastrointestinal disorders | Group A: Sargramostim (Days 1-14) | 1 | 8 | |
| other | Abdominal pain or cramping | Gastrointestinal disorders | Group B: Sargramostim (3 x Week) | 1 | 9 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Group A: Sargramostim (Days 1-14) | 1 | 8 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Group B: Sargramostim (3 x Week) | 0 | 9 | |
| other | Anxiety | Psychiatric disorders | Group A: Sargramostim (Days 1-14) | 1 | 8 | |
| other | Anxiety | Psychiatric disorders | Group B: Sargramostim (3 x Week) | 0 | 9 | |
| other | Arthralgia (joint pain) | Musculoskeletal and connective tissue disorders | Group A: Sargramostim (Days 1-14) | 0 | 8 | |
| other | Arthralgia (joint pain) | Musculoskeletal and connective tissue disorders | Group B: Sargramostim (3 x Week) | 1 | 9 | |
| other | Constipation | Gastrointestinal disorders | Group A: Sargramostim (Days 1-14) | 0 | 8 | |
| other | Constipation | Gastrointestinal disorders | Group B: Sargramostim (3 x Week) | 1 | 9 |
1 to 10 of 100Source ClinicalTrials.gov
See all 100 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group A: Sargramostim (Days 1-14) | ||
| Total, all-cause mortality | Group B: Sargramostim (3 x Week) | ||
| Total, other adverse events | Group A: Sargramostim (Days 1-14) | 8 | 8 |
| Total, other adverse events | Group B: Sargramostim (3 x Week) | 9 | 9 |
| Total, serious adverse events | Group A: Sargramostim (Days 1-14) | 0 | 8 |
| Total, serious adverse events | Group B: Sargramostim (3 x Week) | 2 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | SCHWARTZ, GARY K | CASE WESTERN RESERVE UNIVERSITY | NATIONAL CANCER INSTITUTE | 1987 to 2025 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Group A: Sargramostim (Days 1-14) vs Group B: Sargramostim (3 x Week): Prostate Specific Antigen (PSA) Response | Trial comparisons |
| Group A: Sargramostim (Days 1-14) vs Group B: Sargramostim (3 x Week): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00908141
GET https://conductscience.org/api/trials/v1/NCT00908141/events?page=2